<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">Almanac of Clinical Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Almanac of Clinical Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Альманах клинической медицины</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2072-0505</issn><issn publication-format="electronic">2587-9294</issn><publisher><publisher-name xml:lang="en">Moscow Regional Research and Clinical Institute (MONIKI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1011</article-id><article-id pub-id-type="doi">10.18786/2072-0505-2019-47-020</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>LECTURE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЛЕКЦИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Current approaches to gender dysforia management: an endocrinologist’s perspective</article-title><trans-title-group xml:lang="ru"><trans-title>Современные подходы к ведению гендерной дисфории: взгляд эндокринолога</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Volkova</surname><given-names>N. I.</given-names></name><name xml:lang="ru"><surname>Волкова</surname><given-names>Н. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Natalia I. Volkova</bold> – MD, PhD, Professor, Vice-Сhancellor on Scientific Research, Head of Department of Internal Diseases No. 3,</p><p><italic>29, Nakhichevanskiy pereulok, Rostov-on-Don, 344022</italic></p></bio><bio xml:lang="ru"><p><bold>Волкова Наталья Ивановна</bold> – д-р мед. наук, профессор, проректор по научной работе, заведующая кафедрой внутренних болезней № 3,</p><p><italic>344022, г. Ростов-на-Дону, переулок Нахичеванский, 29</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Davidenko</surname><given-names>I. Yu.</given-names></name><name xml:lang="ru"><surname>Давиденко</surname><given-names>И. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p><bold>Давиденко Илья Юрьевич</bold> – канд. мед. наук, доцент кафедры внутренних болезней № 3,</p><p><italic>344022, г. Ростов-на-Дону, переулок Нахичеванский, 29</italic></p></bio><bio xml:lang="en"><p><bold>Ilya Yu. Davidenko</bold> – MD, PhD, Associate Professor, Department of Internal Diseases No. 3,</p><p><italic>29, Nakhichevanskiy pereulok, Rostov-on-Don, 344022</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Degtyareva</surname><given-names>Yu. S.</given-names></name><name xml:lang="ru"><surname>Дегтярева</surname><given-names>Ю. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p><bold>Дегтярева Юлия Сергеевна</bold> – ординатор кафедры внутренних болезней № 3,</p><p><italic>344068, г. Ростов-на-Дону, ул. Евдокимова, 134</italic></p></bio><bio xml:lang="en"><p><bold>Yuliya S. Degtyareva</bold> – Residen, Department of Internal Diseases No. 3,</p><p><italic>134 Evdokimova ul., Rostov-on-Don, 344068</italic></p></bio><email>i.s.degtiareva@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="ru">ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России</institution></aff><aff><institution xml:lang="en">The Rostov State Medical University</institution></aff></aff-alternatives><content-language>ru</content-language><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2019-05-31"><day>31</day><month>05</month><year>2019</year></pub-date><pub-date date-type="collection"><year>2019</year></pub-date><volume>47</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>166</fpage><lpage>174</lpage><history><date date-type="received" iso-8601-date="2019-04-23"><day>23</day><month>04</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-04-23"><day>23</day><month>04</month><year>2019</year></date></history><pub-history><event event-type="received"><event-desc>Received:<date date-type="received" iso-8601-date="2019-04-23"><day>23</day><month>04</month><year>2019</year></date></event-desc></event><event event-type="accepted"><event-desc>Accepted:<date date-type="accepted" iso-8601-date="2019-04-23"><day>23</day><month>04</month><year>2019</year></date></event-desc></event><event event-type="pub"><event-desc>Published:<pub-date date-type="pub" publication-format="electronic" iso-8601-date="2019-05-31"><day>31</day><month>05</month><year>2019</year></pub-date></event-desc></event></pub-history><permissions><copyright-statement xml:lang="ru">Copyright ©; 2019, Волкова Н.И., Давиденко И.Ю., Дегтярева Ю.С.</copyright-statement><copyright-statement xml:lang="en">Copyright ©; 2019, Volkova N.I., Davidenko I.Y., Degtyareva Y.S.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Волкова Н.И., Давиденко И.Ю., Дегтярева Ю.С.</copyright-holder><copyright-holder xml:lang="en">Volkova N.I., Davidenko I.Y., Degtyareva Y.S.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://almclinmed.ru/jour/article/view/1011">https://almclinmed.ru/jour/article/view/1011</self-uri><abstract xml:lang="en"><p>Understanding of people with impaired gender identity in society, academic and science world is constantly changing due to increased awareness, openness and availability of the information on transgender people and their life. It is known that the social and psychological state of transgenders depends at a  great extent on the quality of their medical care, including hormonal treatment. Unfortunately, until recently the awareness of this problem among many physicians (clinical psychologists, psychiatrists, endocrinologists, etc.) in the Russian Federation remained insufficient, and no unified standards of medical and psychological care for transgender people in Russia have been developed. As a  result, when referring to various specialists, people with impaired gender identity commonly do not receive adequate recommendations and proper comprehensive medical follow-up. An endocrinologist, who prescribes hormonal treatment and performs long-term (usually life-long) follow-up and monitoring of adverse events, is one of the key team members to provide medical care to transgender patients. The article presents current views on definitions, diagnostic criteria and principles of endocrine therapy for gender dysphoria and gender incongruence, as well as highlights medical risks, associated with hormonal treatment, and a monitoring plan for patients receiving corrective therapy.</p></abstract><trans-abstract xml:lang="ru"><p>Представления о людях с нарушенной гендерной идентичностью в  социуме, академических и  научных кругах постоянно меняются в  связи с  повышением осведомленности, открытости и  доступности информации о  трансгендерах и их жизни. Известно, что социальное и психологическое состояние трансгендерных людей во многом зависят от качества предоставляемой медицинской помощи, в  том числе гормонального лечения. Вместе с  тем знания об этой проблеме у  многих врачей (клинических психологов, психиатров, эндокринологов и др.) в Российской Федерации до настоящего времени остаются недостаточными, а  единые стандарты оказания медицинской и  психологической помощи трансгендерным лицам в  России не разработаны. В итоге при обращении к различным специалистам люди с  нарушенной гендерной идентичностью, как правило, не получают адекватных рекомендаций и  надлежащего комплексного медицинского наблюдения. К ключевым членам команды, обеспечивающей медицинскую помощь трансгендерным пациентам, следует отнести врача-эндокринолога, назначающего гормональное лечение и  осуществляющего последующее долгосрочное (пожизненное) наблюдение и  мониторинг нежелательных явлений. В  статье даны современные представления касательно дефиниций, критериев диагностики и  принципов эндокринной терапии гендерной дисфории и половой неконформности, освещены медицинские риски, связанные с  гормональным лечением, а также план мониторинга пациентов, получающих корригирующую терапию.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>эндокринная терапия</kwd><kwd>гендерная дисфория</kwd><kwd>гендерная неконформность</kwd><kwd>трансгендер</kwd></kwd-group><kwd-group xml:lang="en"><kwd>endocrine therapy</kwd><kwd>gender dysphoria</kwd><kwd>gender incongruence</kwd><kwd>transgender</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Bullough VL. Transsexualism in history. Arch Sex Behav. 1975;4(5):561–71. doi: 10.1007/bf01542134.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Benjamin H. The transsexual phenomenon. Trans N Y Acad Sci. 1967;29(4):428–30. doi: 10.1111/j.2164-0947.1967.tb02273.x.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Meyerowitz J. How sex changed: A history of transsexuality in the United States. Cambridge, MA: Harvard University Press; 2002. doi: 10.1086/ahr/108.5.1479.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. The World Professional Association for Transgender Health (WPATH). Standards of Care [Internet]. WPATH; 2017. Available from: https://www.wpath.org/publications/soc/.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. World Health Organization (WHO). New International Classification of Diseases [Internet]. Available from: https://icd.who.int/.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine treatment of gender-dysphoric/ gender-incongruent persons: an Endocrine Society Clinical Practice Guideline. Endocr Pract. 2017;23(12):1437. doi: 10.4158/1934-2403-23.12.1437.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Wierckx K, Van Caenegem E, Pennings G, Elaut E, Dedecker D, Van de Peer F, Weyers S, De Sutter P, T'Sjoen G. Reproductive wish in transsexual men. Hum Reprod. 2012;27(2):483–7. doi: 10.1093/humrep/der406.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. Wierckx K, Stuyver I, Weyers S, Hamada A, Agarwal A, De Sutter P, T'Sjoen G. Sperm freezing in transsexual women. Arch Sex Behav. 2012;41(5): 1069–71. doi: 10.1007/s10508-012-0012-x.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6): 2536–59. doi: 10.1210/jc.2009-2354.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. T'Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of transgender medicine. Endocr Rev. 2019;40(1):97–117. doi: 10.1210/er.2018-00011.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11.Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab. 2008;93(1):19–25. doi: 10.1210/jc.2007-1809.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Lapauw B, Taes Y, Simoens S, Van Caenegem E, Weyers S, Goemaere S, Toye K, Kaufman JM, T'Sjoen GG. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone. 2008;43(6):1016– 21. doi: 10.1016/j.bone.2008.09.001.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. Righini M, Perrier A, De Moerloose P, Bounameaux H. D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost. 2008;6(7):1059–71. doi: 10.1111/j.1538-7836.2008.02981.x.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. Cunha FS, Domenice S, Câmara VL, Sircili MH, Gooren LJ, Mendonça BB, Costa EM. Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy. Andrologia. 2015;47(6): 680–4. doi: 10.1111/and.12317.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15.Nota NM, Dekker MJHJ, Klaver M, Wiepjes CM, van Trotsenburg MA, Heijboer AC, den Heijer M. Prolactin levels during shortand long-term cross-sex hormone treatment: an observational study in transgender persons. Andrologia. 2017;49(6). doi: 10.1111/and.12666.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16. Bunck MC, Debono M, Giltay EJ, Verheijen AT, Diamant M, Gooren LJ. Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages. BMJ Case Rep. 2009;2009. pii: bcr02.2009.1589. doi: 10.1136/bcr.02.2009.1589.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17.Gennari L, Khosla S, Bilezikian JP. Estrogen and fracture risk in men. J Bone Miner Res. 2008;23(10):1548–51. doi: 10.1359/jbmr.0810c.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18. Van Caenegem E, Wierckx K, Taes Y, Schreiner T, Vandewalle S, Toye K, Lapauw B, Kaufman JM, T'Sjoen G. Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI). Eur J Endocrinol. 2015;172(2):163–71. doi: 10.1530/EJE-14-0586.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19. Van Caenegem E, Taes Y, Wierckx K, Vandewalle S, Toye K, Kaufman JM, Schreiner T, Haraldsen I, T'Sjoen G. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone. 2013;54(1):92–7. doi: 10.1016/j.bone.2013.01.039.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20. Shao T, Grossbard ML, Klein P. Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management. Clin Breast Cancer. 2011;11(6):417–9. doi: 10.1016/j.clbc.2011.06.006.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21.Nikolic DV, Djordjevic ML, Granic M, Nikolic AT, Stanimirovic VV, Zdravkovic D, Jelic S. Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy. World J Surg Oncol. 2012;10:280. doi: 10.1186/1477-7819-10-280.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22. Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA; UK Clinical Cytogenetics Group. Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study. Lancet Oncol. 2008;9(3):239–46. doi: 10.1016/S1470-2045(08)70033-0.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with crosssex hormones. Eur J Endocrinol. 2008;159(3): 197–202. doi: 10.1530/EJE-08-0289.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24. Turo R, Jallad S, Prescott S, Cross WR. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. Can Urol Assoc J. 2013;7(7–8):E544–6. doi: 10.5489/cuaj.175.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(3):185–91. doi: 10.7326/0003-4819-149-3-200808050-00008.</mixed-citation></ref></ref-list></back></article>
